4.6 Article

Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report

Journal

ALLERGY
Volume 70, Issue 5, Pages 474-494

Publisher

WILEY
DOI: 10.1111/all.12573

Keywords

classification; endotypes; phenotypes; rhinitis; treatment

Funding

  1. European Academy of Allergy and Clinical Immunology
  2. American Academy of Allergy, Asthma and Immunology

Ask authors/readers for more resources

Rhinitis is an umbrella term that encompasses many different subtypes, several of which still elude complete characterization. The concept of phenotyping, being the definition of disease subtypes on the basis of clinical presentation, has been well established in the last decade. Classification of rhinitis entities on the basis of phenotypes has facilitated their characterization and has helped practicing clinicians to efficiently approach rhinitis patients. Recently, the concept of endotypes, that is, the definition of disease subtypes on the basis of underlying pathophysiology, has emerged. Phenotypes/endotypes are dynamic, overlapping, and may evolve into one another, thus rendering clear-cut definitions difficult. Nevertheless, a phenotype-/endotype-based classification approach could lead toward the application of stratified and personalized medicine in the rhinitis field. In this PRACTALL document, rhinitis phenotypes and endotypes are described, and rhinitis diagnosis and management approaches focusing on those phenotypes/endotypes are presented and discussed. We emphasize the concept of control-based management, which transcends all rhinitis subtypes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Otorhinolaryngology

Determination of the chronic upper airway inflammatory phenotype using a symptom-score-based algorithm

Wout Backaert, Brecht Steelant, Ipek Guler, Karel Talavera, Mark Jorissen, Rik Schrijvers, Peter W. Hellings, Laura Van Gerven

RHINOLOGY (2023)

Review Allergy

Review of evidence supporting the use of nasal corticosteroid irrigation for chronic rhinosinusitis

Jonathan A. Bernstein, Andrew A. White, Joseph K. Han, David M. Lang, David Elkayam, Fuad M. Baroody

Summary: This study aimed to analyze published reports on the efficacy and safety of corticosteroid irrigation (CSI) in chronic rhinosinusitis (CRS) with nasal polyps and evaluate its clinical implications. CSI is commonly used for the treatment of CRS, but it is not approved by the FDA.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Article Allergy

Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology

Sven F. Seys, Peter W. Hellings, Isam Alobid, Vibeke Backer, Emilie Bequignon, Christian von Buchwald, Carlo Cavaliere, Andre Coste, Lauren Deneyer, Zuzana Diamant, Julia Eckl-Dorna, Wytske J. Fokkens, Simon Gane, Philippe Gevaert, Christiane Holbaek-Haase, Clemens Holzmeister, Claire Hopkins, Valerie Hox, Caroline Huart, Roger Jankowski, Mark Jorissen, Anette Kjeldsen, Lisa Knipps, Bibi Lange, Rik van der Lans, Anu Laulajainen-Hongisto, Kenneth Larsen, David T. Liu, Valerie Lund, Gert Marien, Simonetta Masieri, Geoffrey Mortuaire, Joaquim Mullol, Sietze Reitsma, Philippe Rombaux, Sven Schneider, Andreas Steinsvik, Peter-Valentin Tomazic, Sanna K. Toppila-Salmi, Laura Van Gerven, Thibaut Van Zele, Paula Virkkula, Martin Wagenmann

Summary: This study aims to establish an international chronic rhinosinusitis outcome registry based on real-world data collection enabled by mobile health technology. A collaborative scientific network of 17 university ear-nose-throat clinics from 10 European countries has been established to collect data in a longitudinal and standardized manner. Up to 300 patients have already been included.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Allergy

European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis

Philippe Gevaert, Jarno De Craemer, Claus Bachert, Manon Blauwblomme, Adam Chaker, Cemal Cingi, Peter W. Hellings, Claire Hopkins, Valerie Hox, Wytske J. Fokkens, Ludger Klimek, Valerie Lund, Ralph Moesges, Joaquim Mullol, Oliver Pfaar, Glenis Scadding, Peter Valentin Tomazic, Thibaut Van Zele, Stephan Vlaminck, Martin Wagenmann, Sanna Toppila-Salmi, Isam Alobid

Summary: Nasal endoscopy is an important tool for both diagnosis and monitoring of chronic rhinosinusitis with nasal polyps (CRSwNP). Unlike patient-reported outcomes, endoscopic nasal polyp scoring provides an objective measurement that is not influenced by the placebo effect. It is a safer and more cost-effective alternative to computed tomography imaging for assessing the extent of the disease.

ALLERGY (2023)

Editorial Material Allergy

Exercise and physical activity for asthma management: The European Academy of Allergy and Clinical Immunology perspective

Oliver J. Price, Stefano Del Giacco, Radoslaw Gawlik, Christer Janson, Mikaela Odemyr, Nikolaos G. Papadopoulos, Matteo Bonini

ALLERGY (2023)

Article Allergy

Adherence and persistence in allergen immunotherapy (APAIT): A reporting checklist for retrospective studies

Oliver Pfaar, Philippe Devillier, Jochen Schmitt, Pascal Demoly, Ole Hilberg, Lawrence DuBuske, Nicole Hass, Ted Klok, Caroline Beutner

Summary: The 'Adherence and Persistence in AIT (APAIT)' checklist has been developed as a guide for reporting, designing, and interpreting retrospective studies on adherence or persistence to allergen immunotherapy (AIT). The checklist highlights the importance of transparency in reporting and identifies potential sources of bias in these studies.

ALLERGY (2023)

Review Medicine, Research & Experimental

Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review

Jonathan A. Bernstein, Jean-Pierre Llanos, Gillian Hunter, Neil Martin, Christopher S. Ambrose

Summary: This study describes the reduction of annualized asthma exacerbation rate (AAER) from randomized controlled trials (RCTs) in patients with allergic severe asthma. The study found that the efficacy of biologics varied considerably overall and by baseline blood eosinophil count (BEC), with tezepelumab consistently demonstrating the greatest reduction in AAER across all subgroups.

ADVANCES IN THERAPY (2023)

Article Allergy

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy

P. J. de Kam, S. Zielen, J. A. Bernstein, U. Berger, M. Berger, M. Cuevas, D. Cypcar, A. Fuhr-Horst, W. A. Greisner, M. Jandl, S. Lassmann, M. Worm, J. Matz, E. Sher, C. Smith, G. C. Steven, R. Moesges, M. H. Shamji, L. DuBuske, F. Borghese, K. Oluwayi, T. Zwingers, M. Seybold, O. Armfield, M. D. Heath, S. J. Hewings, M. F. Kramer, M. A. Skinner

Summary: The study evaluated the efficacy and safety of a modified grass allergen subcutaneous immunotherapy for grass-pollen allergic rhinitis/rhinoconjunctivitis. The results showed clinically relevant and statistically significant improvements in symptom and medication scores, as well as a good safety profile.

ALLERGY (2023)

Review Allergy

Addressing adverse synergies between chemical and biological pollutants at schools-The 'SynAir-G' hypothesis

Nikolaos G. Papadopoulos, Cezmi Akdis, Mubeccel Akdis, Athanasios Damialis, Giuseppina Esposito, Ioana Fergadiotou, Christian Goroncy, Pierre Guitton, Maia Gotua, Kleanthis Erotokritou, Tuomas Jartti, Clare Murray, Athanasios Nenes, Sotirios Nikoletseas, Susetta Finotto, Spyros N. Pandis, Valeria Ramiconi, Angela Simpson, Aki Soudunsaari, Anna Starbrost, Maria Staiano, Antonio Varriale, Paraskevi Xepapadaki, Torsten Zuberbier, Isabella Annesi-Maesano

Summary: While the number and types of indoor air pollutants is increasing, little is known about the impact of their synergistic interactions on human health. Different populations have varying susceptibility to pollutants, and low socioeconomic backgrounds further contribute to susceptibility. The SynAir-G project aims to understand and quantify the interactions between different pollutants in order to improve targeting and standards, specifically in the school setting. It will develop a comprehensive monitoring system, advance environmentally friendly interventions, and disseminate knowledge to stakeholders.

ALLERGY (2023)

Editorial Material Allergy

Recall urticaria with infusion of agalsidase beta

Raagini Suresh Yedidi, Jonathan A. Bernstein

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2023)

Article Anesthesiology

Pholcodine exposure increases the risk of perioperative anaphylaxis to neuromuscular blocking agents: the ALPHO case-control study

Paul Michel Mertes, Nadine Petitpain, Charles Tacquard, Marion Delpuech, Cedric Baumann, Jean Marc Malinovsky, Dan Longrois, Aurelie Gouel-Cheron, Diane Le Quang, Pascal Demoly, Jean Louis Gueant, Pierre Gillet, ALPHO Study Grp

Summary: This study assessed the relationship between pholcodine exposure and NMBA-related anaphylaxis. It found that exposure to pholcodine and other quaternary ammonium compounds in the environment can increase sensitivity to NMBAs. Pholcodine and quaternary ammonium sIgEs have a high negative predictive value but a very low positive predictive value for identifying NMBA-related reactions.

BRITISH JOURNAL OF ANAESTHESIA (2023)

Review Allergy

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?

Dorien Van Broeck, Brecht Steelant, Glenis Scadding, Peter W. Hellings

Summary: Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a clinical syndrome characterized by nasal polyposis, asthma, and intolerance to aspirin/NSAID. It affects approximately 15% cases of severe asthma, 10% of nasal polyps and 9% of rhinosinusitis. N-ERD results in associated asthma exacerbations, oral corticosteroids bursts, corticosteroid-dependent disease, and multiple endoscopic sinus surgeries. Unknown influences cause polyp epithelium to release alarmins, activating lymphoid cells and causing complex type 2 inflammation. Treatment strategies for N-ERD include drug therapies, aspirin desensitization, monoclonal antibodies, and other therapies associated.

FRONTIERS IN ALLERGY (2023)

Article Allergy

Determinants of uncontrolled allergic rhinitis in Kinshasa hospitals

Patricia K. Kakobo, Hilaire K. Kalala, Joseph K. Kelekele, Paulin B. Mutombo, Dieudonne T. Nyembue, Peter W. Hellings, Jean-Marie N. Kayembe

Summary: This study aims to identify the determinants of uncontrolled allergic rhinitis (UCAR) in a hospital setting in Kinshasa, Democratic Republic of Congo. The study found that factors associated with UCAR include age below 30 years, low vitamin D level, and persistent as well as moderate to severe allergic rhinitis.

FRONTIERS IN ALLERGY (2023)

Article Allergy

Telemedicine with special focus on allergic diseases and asthma-Status 2022: An EAACI position paper

Sylwia Smolinska, Florin-Dan Popescu, Elena Izquierdo, Dario Antolin-Amerigo, Oliver J. Price, Alberto Alvarez-Perea, Ibon Eguiluz Gracia, Nikolaos G. Papadopoulos, Oliver Pfaar, Filippo Fassio, Karin Hoffmann-Sommergruber, Stephanie Dramburg, Ioana Agache, Marek Jutel, Helen A. Brough, Joao A. Fonseca, Elizabeth Angier, Cristina Boccabella, Matteo Bonini, Audrey Dunn Galvin, Peter G. Gibson, Radoslaw Gawlik, Farah Hannachi, Oemer Kalayci, Ludger Klimek, Rebecca Knibb, Paolo Matricardi, Tomas Chivato

Summary: This article aims to describe effective telemedicine communication between healthcare professionals and patients. The article discusses the terminology, important forms, and applications of telemedicine in asthma and allergies. It concludes that telemedicine reduces costs and time but cannot fully replace face-to-face visits. Additionally, confidentiality and information security are important from an ethical perspective.

ALLERGY (2023)

Article Allergy

A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema

Remy S. Petersen, Laura Bordone, Marc A. Riedl, Raffi Tachdjian, Timothy J. Craig, William R. Lumry, Michael E. Manning, Jonathan A. Bernstein, Jason Raasch, Bruce L. Zuraw, Yiwen Deng, Kenneth B. Newman, Veronica J. Alexander, Cindy Lui, Eugene Schneider, Danny M. Cohn

Summary: The 2-year interim results of this phase 2 open-label extension study of donidalorsen in patients with HAE demonstrated no new safety signals. Donidalorsen was well tolerated with durable efficacy, resulting in a 96% reduction in HAE attacks.

ALLERGY (2023)

No Data Available